HHS goes live with online locator of COVID-countering therapeutic drugs

The U.S. Department of Health and Human Services has posted an interactive map showing the locations of drug distributors that have recently received shipments of two monoclonal antibody medications good for treating COVID-19.

The drugs, Eli Lilly’s Bamlanivimab preparation and Regeneron’s Casirivimab/Imdevimab cocktail, were OK’d for emergency use by the FDA in November.

Drugs in this class are manufactured proteins that imitate natural immune responses to counter viruses and other pathogens.

HHS intends the map for use by outpatients as well as providers.

Robert Kadlec, MD, the HHS’s assistant secretary for preparedness and response, says use of the treatment locator “may help reduce the number of people who require hospitalization for COVID-19 care, which in turn reduces the strain on our nation’s hospitals and their staff.”

The agency notes that states and, with them, distribution sites, may opt out of the map listings.

Access the map here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”